Why the study?
Intensive BP treatment in SPRINT reduced ADHF events, but its specific effects on HFpEF versus HFrEF and their subsequent outcomes remained to be reported.
Does intensive BP treatment reduce incident acute decompensated heart failure (HFpEF and HFrEF) and alter subsequent outcomes in SPRINT participants?
Does intensive BP treatment reduce incident acute decompensated heart failure (HFpEF and HFrEF) and alter subsequent outcomes in SPRINT participants?
Intensive BP reduction decreases incident ADHF regardless of EF subtype, but does not alter the high subsequent risk of mortality or readmission once ADHF occurs.
Answers are grounded in this paper and cite their sources.
Intensive BP control may reduce incident HFpEF and HFrEF; post-hoc SPRINT analysis leaves open effects on subsequent outcomes.
BACKGROUND: In the SPRINT (Systolic Blood Pressure Intervention Trial), intensive BP treatment reduced acute decompensated heart failure (ADHF) events. Here, we report the effect on HF with preserved ejection fraction (HFpEF) and HF with reduced EF (HFrEF) and their subsequent outcomes. METHODS: Incident ADHF was defined as hospitalization or emergency department visit, confirmed, and formally adjudicated by a blinded events committee using standardized protocols. HFpEF was defined as EF ≥45%, and HFrEF was EF <45%. RESULTS: value: 0.73). During average 3.3 years follow-up in those who developed incident ADHF, rates of subsequent all-cause and HF hospital readmission and mortality were high, but there were no significant differences between those who developed HFpEF versus HFrEF. Randomization to the intensive arm had no effect on subsequent mortality or readmissions after the initial ADHF event, irrespective of EF subtype. During follow-up among participants who developed HFpEF, although relatively modest number of events limited statistical power, age was an independent predictor of all-cause mortality, and Black race independently predicted all-cause and HF hospital readmission. CONCLUSIONS: In SPRINT, intensive BP reduction decreased both acute decompensated HFpEF and HFrEF events. After initial incident ADHF, rates of subsequent hospital admission and mortality were high and were similar for those who developed HFpEF or HFrEF. Randomization to the intensive arm did not alter the risks for subsequent all-cause, or HF events in either HFpEF or HFrEF. Among those who developed HFpEF, age and Black race were independent predictors of clinical outcomes. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01206062.
No takes yet. Share an insight, caveat, or question.
Upadhya et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: